Clinically Indicated, Equitable Care for Ischemic Heart Disease in CKD: A Call to Action
- PMID: 37000953
- PMCID: PMC10103196
- DOI: 10.1681/ASN.0000000000000100
Clinically Indicated, Equitable Care for Ischemic Heart Disease in CKD: A Call to Action
Conflict of interest statement
G.M. Chertow reports consultancy: Akebia, Ardelyx, AstraZeneca, Gilead, Miromatrix, Reata, Sanifit, Unicycive, and Vertex; ownership interest: Ardelyx, CloudCath, Durect, DxNow, Eliaz Therapeutics, Outset, Physiowave, PuraCath, Renibus, and Unicycive; research funding: NIAID and NIDDK; advisory or leadership role: Board of Directors, Satellite Healthcare and Co-Editor,
Comment on
-
Utilization and Outcomes of Clinically Indicated Invasive Cardiac Care in Veterans with Acute Coronary Syndrome and Chronic Kidney Disease.J Am Soc Nephrol. 2023 Apr 1;34(4):694-705. doi: 10.1681/ASN.0000000000000067. Epub 2023 Jan 5. J Am Soc Nephrol. 2023. PMID: 36735537 Free PMC article.
References
-
- United States Renal Data System. USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2022.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
